Richard I. Steinhart's most recent trade in BioXcel Therapeutics Inc was a trade of 35 Restricted Stock Units done . Disclosure was reported to the exchange on June 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2025 | 35 | 352 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2025 | 35 | 1,441 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2025 | 33 | 1,406 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2025 | 33 | 196 | - | - | Restricted Stock Units | |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 387 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 1,373 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 1,339 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 229 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 5,064 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 21,362 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 20,800 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 2,606 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 14 Dec 2024 | 372 | 20,932 (0%) | 0% | 0.4 | 133 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 14 Dec 2024 | 205 | 21,157 (0%) | 0% | 0.4 | 74 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2024 | 21,250 | 27,454 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 17 Sep 2024 | 7,175 | 20,279 (0%) | 0% | 0.5 | 3,946 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 6,560 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 5,625 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 5,997 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 3,127 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.69 per share. | 14 Sep 2024 | 356 | 6,204 (0%) | 0% | 0.7 | 246 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 1,875 | 1,875 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 625 | 625 | - | - | Restricted Stock Units | |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 5,848 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 6,188 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 5,286 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 3,648 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 14 Jun 2024 | 372 | 5,476 (0%) | 0% | 1.3 | 470 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 6,750 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 5,834 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.64 per share. | 14 Mar 2024 | 1,069 | 4,765 (0%) | 0% | 2.6 | 2,817 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 4,169 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 3,584 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Steinhart Richard I. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 3,063 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Steinhart Richard I. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 4,690 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 5,211 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 2,542 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 5,732 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 2,021 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.17 per share. | 14 May 2023 | 5,000 | 1,500 (0%) | 0% | 27.2 | 135,864 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 5,000 | 0 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 5,000 | 6,500 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 6,253 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.50 per share. | 14 Mar 2023 | 2,084 | 1,500 (0%) | 0% | 19.5 | 40,638 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 3,584 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Senior VP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2022 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 50,000 | 500,000 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 33,350 | 33,350 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 8,337 | 8,337 | - | - | Restricted Stock Units | |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.55 per share. | 01 Feb 2021 | 3,750 | 5,250 (0%) | 0% | 5.6 | 20,813 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 3,750 | 80,148 | - | - | Stock Option | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.15 per share. | 01 Feb 2021 | 3,750 | 1,500 (0%) | 0% | 48.2 | 180,563 | Common Stock |